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ABSTRACT Human parainﬂuenza viruses cause a large burden of human respiratory
illness. While much research relies upon viruses grown in cultured immortalized
cells, human parainﬂuenza virus 3 (HPIV-3) evolves in culture. Cultured viruses differ
in their properties compared to clinical strains. We present a genome-wide survey of
HPIV-3 adaptations to culture using metagenomic next-generation sequencing of
matched pairs of clinical samples and primary culture isolates (zero passage virus).
Nonsynonymous changes arose during primary viral isolation, almost entirely in the
genes encoding the two surface glycoproteins—the receptor binding protein
hemagglutinin-neuraminidase (HN) or the fusion protein (F). We recovered genomes
from 95 HPIV-3 primary culture isolates and 23 HPIV-3 strains directly from clinical
samples. HN mutations arising during primary viral isolation resulted in substitutions
at HN’s dimerization/F-interaction site, a site critical for activation of viral fusion. Alterations in HN dimer interface residues known to favor infection in culture occurred
within 4 days (H552 and N556). A novel cluster of residues at a different face of the
HN dimer interface emerged (P241 and R242) and imply a role in HPIV-3-mediated
fusion. Functional characterization of these culture-associated HN mutations in a
clinical isolate background revealed acquisition of the fusogenic phenotype associated with cultured HPIV-3; the HN-F complex showed enhanced fusion and decreased receptor-cleaving activity. These results utilize a method for identifying
genome-wide changes associated with brief adaptation to culture to highlight the
notion that even brief exposure to immortalized cells may affect key viral properties
and underscore the balance of features of the HN-F complex required for ﬁtness by
circulating viruses.

Human parainﬂuenza virus 3 is an important cause of morbidity and
mortality among infants, the immunocompromised, and the elderly. Using deep
genomic sequencing of HPIV-3-positive clinical material and its subsequent viral isolate, we discover a number of known and novel coding mutations in the main
HPIV-3 attachment protein HN during brief exposure to immortalized cells. These
mutations signiﬁcantly alter function of the fusion complex, increasing fusion promotion by HN as well as generally decreasing neuraminidase activity and increasing
HN-receptor engagement. These results show that viruses may evolve rapidly in cul-

IMPORTANCE

July/August 2018 Volume 9 Issue 4 e00898-18

Received 23 April 2018 Accepted 6 June
2018 Published 3 July 2018
Citation Iketani S, Shean RC, Ferren M,
Makhsous N, Aquino DB, des Georges A, Rima
B, Mathieu C, Porotto M, Moscona A, Greninger
AL. 2018. Viral entry properties required for
ﬁtness in humans are lost through rapid
genomic change during viral isolation. mBio
9:e00898-18. https://doi.org/10.1128/mBio
.00898-18.
Editor Mark R. Denison, Vanderbilt University
Medical Center
Copyright © 2018 Iketani et al. This is an openaccess article distributed under the terms of
the Creative Commons Attribution 4.0
International license.
Address correspondence to Anne Moscona,
am939@cumc.columbia.edu, or Alexander L.
Greninger, agrening@uw.edu.
S.I., R.C.S., and M.F. made equal contributions to
this study.

®

mbio.asm.org 1

Iketani et al.

®

ture even during primary isolation of the virus and before the ﬁrst passage and reveal features of ﬁtness for humans that are obscured by rapid adaptation to laboratory conditions.
KEYWORDS entry mechanisms, lung infection, metagenomics, parainﬂuenza virus,
paramyxovirus, viral evolution, viral ﬁtness, viral fusion

H

uman parainﬂuenza viruses are enveloped single-stranded negative-sense RNA
viruses in the Paramyxoviridae family that account for a signiﬁcant amount of
human respiratory illnesses, especially in infants, children, and hematopoietic cell
transplant patients and other immunocompromised individuals (1, 2). Of these, human
parainﬂuenza virus 3 (HPIV-3) is the most commonly isolated parainﬂuenza virus (3). It
has recently become clear that the process whereby HPIV-3 binds and enters host cells
is ﬁnely tuned for interaction with the correct host cell environment (4–7).
Two surface glycoproteins of HPIV-3, the hemagglutinin-neuraminidase (HN) and
fusion (F) proteins, work in concert to mediate fusion into the target host cell during
infection. HN is a tetramer that carries out several functions in addition to serving as the
receptor binding protein for the virus by binding to sialic acids (8). When HN is bound
to a receptor, it activates F to a fusion ready state. Once activated, F inserts itself into
the target membrane and undergoes a series of conformational changes that lead to
fusion. Structural rearrangement of the F protein drives the cell-associated fusion
peptide toward the viral membrane, bringing the two membranes into proximity and
facilitating membrane fusion and viral entry (9, 10). HN also stabilizes the prefusion
state of F prior to receptor engagement (11) and cleaves the receptor via its neuraminidase activity during viral budding (9, 12). These properties act together during infection of a target cell, when HN must signal the F protein, inducing the series of
conformational shifts in F that result in fusion of the viral membrane with the host cell
membrane at the correct time and place in the highly specialized human airway
microenvironment (7). Such critical functions place the HN protein and HN-F fusion
complex under signiﬁcant selective pressure.
Each feature of HN, and the balance between the pro- and antifusion properties of
the HN-F fusion complex, modulates ﬁtness for infection of humans (6), meaning in this
study, the relative ability to replicate in a given host tissue. Signiﬁcant differences in
properties governed by HN and the HN-F interaction exist between cultured laboratory
and clinical strains in the HN and F proteins, and these differences point to the
requirements for infection in each environment (4). HPIV-3 adapts to culture via
increased fusion activity, whether by HN’s increased avidity for receptor, enhanced
activation of F, or reduced receptor cleavage that results in enhanced receptor contact
and fusion (4–7). Evaluation of a panel of clinical strains that were deep sequenced
without passage in immortalized monolayer cultures and which were grown only in
primary human airway epithelium (HAE)—revealed functional differences in the HN-F
fusion complex and a phenotype of less active fusion activation in the clinical viruses
(4). The preservation of these functional features in the panel of clinical isolates during
growth in human airway suggested that mitigating fusion may be important for ﬁtness
in vivo.
Such stark differences in pressures exerted by in vitro and in vivo conditions have
notable consequences which have been observed and characterized in other systems
in addition to HPIV-3. For example, passaging of inﬂuenza A virus in eggs during
vaccine production results in adaptations that alter its antigenicity (13, 14), and cell
culture adaptation of hepatitis C virus impairs its ﬁtness in vivo (15). These and other
studies (16–22) have delineated the importance of characterizing clinical viruses, as well
as the need to investigate viral evolution in authentic tissues and the biological
signiﬁcance of such adaptations. In fact, based on evaluation of a set of clinical strains
compared to laboratory strains and to other available sequences (4), we hypothesized
that adaptation to culture conditions might occur so rapidly that by virtue of growing
the viruses to sequence, the strains published as being clinical may have actually
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altered to suit cultured cells and could no longer be considered clinical strains. There
has been a relative dearth of sequence information available for HPIV compared to
other respiratory viruses (23), and more importantly a lack of information about strains
prior to passaging in the laboratory and thereby being subjected to selective pressure.
To address the question of which features associated with ﬁtness in humans may be
lost in routine viral culture, we sought to understand the genomic changes associated
with brief exposure of HPIV-3 from clinical samples to culture during the isolation
process. We used metagenomic next-generation sequencing (mNGS) of ﬁeld strains of
HPIV-3 isolated from humans to analyze the diversity and commonalities of circulating
HPIV-3 strains at the genomic level, and we simultaneously sequenced paired specimens that were subjected to culture for viral isolation. The sequencing strategy we
used to sequence clinical strains directly without passage in immortalized cells does not
rely on designing sequence-speciﬁc primers that may amplify only a subset of samples
(in case of mutations) (24). Deep genomic sequencing of nine sets of paired clinical
samples (primary nasal swabs in viral transport medium) and culture isolates (culture
harvest from zero passage virus) led to discovery of a number of HN mutations
associated with rapid evolution in culture. To assess the frequency of mutations
identiﬁed earlier, we also performed deep sequencing of 118 HPIV-3 clinical samples
and culture isolates from the University of Washington Virology Laboratory, allowing us
to conﬁrm that the alterations associated with brief exposure to culture for viral
isolation were almost entirely found in the sequences of culture isolates and found
commonly within populations of viruses in those isolates.
Functional characterization of the effects of several of the speciﬁc HN gene mutations found in the cultured isolates in a clinical isolate (CI) background—in expressed
HN-F complexes or recombinant viruses bearing the mutated genes—reveals that the
culture-associated mutations all increase fusion promotion by the HN-F complex. These
results support the notion that clinical strains differ from cultured viruses in the balance
of fusion properties. The locations of the residues that differ after brief culture of clinical
viruses point to speciﬁc domains that are relevant to the control of viral entry in vivo.
The sequencing data, when correlated to functional data, help deﬁne the ﬂexibility and
constraints of the HPIV-3 fusion complex. These data provide the ﬁrst characterization
of culture-associated HN mutations in the background of HPIV-3 clinical strains directly
from patient samples. We show that, even during transient exposure to culture (“zero
passage” virus), the act of isolating a virus is associated with genomic evolution that
may signiﬁcantly affect viral protein function and not reﬂect in vivo dynamics.
RESULTS
Mutation and mixed allele frequency comparison between clinical samples and
their matched cultured specimens. To compare HPIV-3 sequenced directly from
patients with HPIV-3 sequenced after brief growth in culture, nine HPIV-3-positive
(HPIV-3⫹) nasal swabs were sequenced metagenomically, and their paired viral isolates
were sequenced after initial isolation in rhesus monkey kidney (RhMK) cells. We
investigated the variant alleles with a minor allele frequency of ⬎5% that arose in
culture. The nine swabs included one clinical sample that was independently cultured
twice, such that ten viral isolates were sequenced. Clinical respiratory samples that
tested positive for HPIV-3 by quantitative reverse transcription-PCR (qRT-PCR) with
cycle thresholds under 25 were either sequenced directly by metagenomic nextgeneration sequencing (mNGS) without exposure to culture or grown on RhMK cells
and viral isolates were harvested and sequenced. The choice of RhMK cells for this study
was based on the fact that these are the standard cells used for viral isolation by many
or most diagnostic microbiology laboratories and would allow us to answer the
question of whether this standard process leads to alteration in the viruses.
Seven of the nine cultured isolates were harvested before day 5 of culture, and no
viruses were passaged beyond initial isolation. Sequencing reads for the cultured
viruses were analyzed for mutational changes relative to the HPIV-3 consensus genome
obtained from metagenomic sequencing of the original clinical sample (without expoJuly/August 2018 Volume 9 Issue 4 e00898-18
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FIG 1 Mutational changes and allele frequencies in matched clinical samples and cultures. Blue genomes represent clinical samples, and the green genomes
below the blue genomes represent the same sample after it was inoculated into culture and harvested several days later. The number of days cultured,
hemagglutinin adsorption assay results (HAD), and observed cytopathic effect (CPE) are shown for each viral isolate. Virus from sample SC1784 in panel G was
isolated twice. Coverage is averaged across the entire genome and depicted underneath each genome. Allele frequencies are plotted to scale above the
genome organization. Mutational changes are described relative to the amino acid in the consensus genome of the original patient sample. Variants indicated
in italics were found exclusively on separate reads and are considered unlinked.

sure to any cell culture), and both assemblies were analyzed for variants with ⬎5%
minor allele frequency (MAF) (25).
A total of 28 nonsynonymous mutational changes with MAF change of ⬎5% in
response to exposure to cell culture were found across the nine sets of HPIV-3 viral
isolates, with 18 of the 28 in the HN protein (P ⬍ 0.001 by Fisher’s exact test) (Fig. 1).
Of the ten mutations found outside the HN protein, four were found in the P protein,
four in the L protein, and two in the F protein. Of the two L variants that increased in
allele frequency in cultured specimens, one (G1759D) was not found in a separate viral
isolation performed on the same clinical sample, while the other (P104L) was found at
a high allele frequency in the original clinical sample (Fig. 1D to G). Evolution of the
polymerase complex will be explored separately, as the focus of this current paper is on
the entry complex.
During viral isolation from sample SC1784, we noted the appearance of the previously described HN H552Q mutation at 35% MAF after only 4 days in culture (Fig. 1G).
HN H552Q has previously been isolated in laboratory-adapted HPIV-3 strains and is
July/August 2018 Volume 9 Issue 4 e00898-18
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associated with enhanced fusion promotion as a result of HN’s F-triggering function (7,
26–28). Two independent viral isolations in RhMK cells of this clinical sample resulted
in selection for the HN H552Q variant allele.
During viral isolation in RhMK cells from sample SC3238, an HN N556D mutation
emerged from 0% to 71% allele frequency in only 4 days, the greatest change in allele
frequency during the brief exposure to culture (Fig. 1E). Previous comparison of direct
clinical isolates with laboratory-adapted strains showed that every clinical strain bore
asparagine (N) at position 556, while our laboratory strains bore aspartic acid (D) at
position 556 (4). The HNs derived from clinical isolates (CIs) showed from 4- to
10-fold-higher neuraminidase activity than HNs derived from the lab-adapted strains,
and the substitution of the aspartic acid at this position in the laboratory strains led to
an approximately 5-fold-lower receptor cleavage in the laboratory-adapted strains,
suggesting that the asparagine at position 556 is essential for the high propensity for
receptor cleavage in ﬁeld strains. The rapid emergence of this adaptation to culture by
reducing receptor cleavage is remarkable.
During viral isolation from both samples SC0129 and SC2155, an HN L555S mutation, adjacent to residues 552 and 556 mentioned above, arose to 24% and 43% MAF
(Fig. 1A to I). During isolation of sample SC1784, the same site contained an L555F
mutation that was unlinked to the H552Q mutation that also arose during that isolation
(i.e., was found exclusively on separate reads). The SC1201 isolation also resulted in
selection of novel mutations HN S554N and HN T557I, comprising a cluster from
positions 552 to 557 with signiﬁcant alterations in the cultured viruses (Fig. 1H).
While the region of HN corresponding to the cluster at positions 552 to 557 above
was known to be of interest for entry in vivo (based on features of H552 and N556),
during independent viral isolations from sample SC1784, a set of mutations emerged in
HN at residues previously unrecognized to be relevant to ﬁtness: P241 and R242 (HN
P241L and HN R242K). These mutations were not linked to each other. The P241L
mutation described above was also recovered during viral isolations of SC2565 and
SC1201 (Fig. 1C to H). Adjacent to these residues, another previously undescribed HN
mutation L239F was selected at a high allele frequency (64%) during isolation of
SC2711 and at a low level during isolation of SC1784 (5% MAF in 16K4 and 3% MAF in
CUL1784). As discussed further below, these three residues describe a region of interest
based on our previous structural analysis of the HN dimer interface (6).
Phylogeny and HN mutation history in original samples. To dissect the inﬂuence
exerted by background HN sequence of the clinical virus on subsequent culture
adaptation, we generated a phylogenetic tree based on amino acid substitution
distance in the HN protein of our clinical samples (Fig. 2). None of the phylogenydetermining mutations among direct clinical sample strains were located in HN’s
receptor binding site II or second dimer interface domain that emerged during rapid
culture adaptation. Independent viral isolates from sample SC1784 (16K4 and CUL1784)
produced P241L, R242K, and H552Q. The HN mutations L239F, P241L, S554N, and L555S
also arose among separate lineages.
Large-scale whole-genome sequencing of HPIV-3 direct- and culture-exposed
strains shows that culture-associated mutations are rarely found in clinical
strains. To place the alleles that arose in the paired clinical-culture specimens above in
the broader context of HPIV-3 sequence information, we used mNGS to obtain whole
genomes from an additional 118 HPIV-3 strains, 95 of which were primary viral isolates
(passage zero virus; brief exposure to culture only during viral isolation) and the
remaining 23 were directly from patient samples. All specimens were collected in 2015
or 2016 (see Table S1 in the supplemental material). Recombination analysis using RDP4
(29, 30) revealed no recombination among these strains similarly to other nonsegmented negative-strand RNA viruses (29, 30). Phylodynamic analysis of the concatenated coding regions of the 118 HPIV-3 sequenced strains revealed a mean mutation
rate of 5.948E⫺4 substitutions/site/year (95% conﬁdence interval, 3.8463E⫺4 to
7.1847E⫺4). Analysis of concatenated coding regions from all 243 HPIV-3 sequences
with complete coding sequences (CDS) in the GenBank NT database as of 7 September
July/August 2018 Volume 9 Issue 4 e00898-18
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2017 revealed a similar mean mutation rate of 3.12E⫺4 substitutions/site/year (95%
conﬁdence interval, 2.33E⫺4 to 4.02E⫺4) similar to those of other paramyxoviruses
(31).
Phylogenetic analysis of the newly sequenced HPIV-3 coding sequences revealed
multiple lineages of HPIV-3 present in 2015–2016 clinical samples and clustering by
time of collection as the dominant feature rather than by sequence obtained from viral
isolate versus clinical sample (Fig. 3). However, examination of the deep sequencing
data for 36 of the 95 viral isolates revealed mutations with ⬎5% MAF in residues 241
and 242 and residues 552 to 557 selected during the paired sample-isolate analysis
above. While the original clinical samples for these isolates are not available, none of
the clinical samples sequenced metagenomically contained variant residues at these
loci. Of the 36 strains with variant residues, only 3 viral isolates and 2 laboratoryadapted strains contained variant residues with ⬎50% MAF that would be expected to
be reﬂected in consensus sequence available publicly.
In addition to the newly derived HPIV-3 genome sequences, we also examined all
complete and partial consensus HPIV-3 HN sequences available in the GenBank NT
database as of 18 August 2017—a total of 1,178 sequences—in a search for the
culture-associated mutations isolated here. Of the culture-associated mutations in the
HN protein described above, P241L (3), S554N (1), L555F (4), L555S (7), N556D (13), and
T557I (2) appeared exclusively in sequences from cultured isolates (28, 32–37). None of
the consensus sequences in NCBI with a P241L mutation had a mutation in the 552 to
557 residue range (consensus sequence, 552-HKSLNT-557). The H552Q mutation appeared previously in 15 sequences, with the vast majority of these (11/15) occurring in
culture isolates; note that as above, even sequences listed as clinical may have
experienced brief exposure to culture conditions. The L239F mutation has not been
reported in any consensus HPIV-3 HN sequence in NCBI.
July/August 2018 Volume 9 Issue 4 e00898-18
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10F1
12N3
9S5 L555S (27.8%)
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2P2 P241L (17.4%)
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10E2 P241L (6.3%)
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H552Q (100%)
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FIG 3 Whole-genome sequencing of 95 HPIV-3 primary viral isolates and 23 HPIV-3-positive clinical samples from excess samples at the University of
Washington Virology Laboratory. All specimens were collected from 2009 to 2016. Clinical “SC” HPIV-3 genomes shown in blue were sequenced metagenomically directly from patient samples, while viral isolates are shown in green. HPIV-3 sequences from clinical samples from the original matched sample are shown
as brown stars. At the bottom, 16F7 is shown in red, as it is a likely culture-adapted College of American Pathologists proﬁciency testing sample, and 16G3 is
pink because it was isolated over a 14-day period at the same time 16F7 was being cultured and is a potential 16F7 contaminant. Posterior support values are
shown next to branches with gray scale gradient shading from black at 0.7 to very light gray at 0. The scale at the bottom of the ﬁgure shows the collection
date for each sample.

Three instances of the R242K alteration were found in NCBI GenBank (28, 38). One
of these was recovered using RT-PCR directly from clinical specimens during an HPIV-3
outbreak in a children’s hospital cancer ward in Barcelona, Spain, in summer 2012 (38).
The remaining two R242K mutations reported were from a likely culture-adapted
College of American Pathologists proﬁciency testing sample (strain 16F7, GenBank
accession no. KY674982) and a primary culture isolate from Japan (DDBJ accession no.
AB623431) (28).
HPIV-3 culture adaptations localize to the dimer interface of HN. We mapped all
the residue changes in the HN protein that arose during adaptation to brief culture
onto the HPIV-3 HN protein crystal structure 4WEF (Fig. 4). All alterations localized to
the dimer interface. We previously described critical residues at the HN dimer interface
for HN’s roles in receptor engagement and activation of F at H552—which we identiﬁed
as the secondary sialic acid binding site—and in receptor cleavage at N556, shown at
the top of the HN globular head dimer interface in the diagram (Fig. 4). The diagram
highlights the fact that N556 likely makes contact with the NAc modiﬁcation of N523,
and glycosylation could therefore have a signiﬁcant effect on binding. We have shown
that alterations that enhanced dimer contacts were associated with culture adaptation,
while host ﬁtness was correlated with reduced dimer contacts at these residues (6).
Alterations in residues 552 and 556 have been associated with other culture conditions
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FIG 4 Mapping of minor alleles that arose during culture onto the PDB 4WEF HPIV-3 HN crystal structure. The diagram shows the interface
between the globular heads of two monomers, including receptor binding site II known to be critical for activation of F (discussed in text).
At the top are sites located between residues 552 and 556 where we found minor allele variations in culture. At the bottom of the diagram,
residues 239 and 242 are shown, where minor allele variations also arose from culture. Side chains are shown as they are in the reference
strain—not the mutations that we noted.

as well (5–7), supporting the notion that this site is intimately involved in the mechanism whereby HN activates F in the natural host. The mutations P241L and R242K have
not been described before and appear in a cluster at the opposing side of the dimer
interface. The rapid emergence of alterations here during adaptation of a patient’s
HPIV-3 to culture suggests a role in viral entry in the natural host. Of note, P241 does
not make speciﬁc contact with the opposing monomer, but a mutation would change
the conformation of the loop signiﬁcantly, thereby altering the contacts that the loop
can have.
HN mutations in site II and dimer interface modulate fusion promotion. To
understand the selection forces that affect HPIV-3 ﬁtness, we next analyzed the
biological properties conferred by the culture-associated mutations in HN. Here we
characterized the inﬂuence of each speciﬁc residue on the function of the HN-F fusion
complex. To investigate whether the identiﬁed mutations altered HN’s fusion promotion ability we had previously observed in clinical isolates of HPIV-3, we introduced
seven of these rapidly emerging mutations into the background of a well-characterized
clinical isolate HN, clinical isolate 1 (CI-1) (4, 5). We paired these mutated HN proteins
with a lab-adapted F to ensure that we could observe adequate levels of fusion to
compare function, since clinical isolate HN and F pairs result in nearly unobservable
levels of fusion (4). Fusion promotion by each of these mutant HN-F pairs was
quantiﬁed with a ␤-galactosidase complementation assay and compared to the wildtype clinical isolate HN (CI WT) paired with the lab-adapted F (Fig. 5). We included an
inﬂuenza A virus hemagglutinin (HA) and F pair as a positive control for fusion, as it had
been previously shown that HN has a stabilizing property that prevents F triggering;
that is, an increase in fusion relative to the CI WT would be expected and was seen (11).
The fusion exhibited by all mutant HN-F pairs was considerably higher than that of the
CI WT HN-F pair, ranging from a 20-fold increase (HN S554N) to a 100-fold increase (HN
L555F).
Neuraminidase activity is reduced by HN’s adaptations to culture except for
H552Q. After observing that fusion promotion was increased by all HN mutants, we
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FIG 5 HN adaptations to culture increase fusion promotion by viral fusion complex. Cells were
cotransfected with the indicated HN in a clinical isolate background, reference F, and the ␣ fragment of
␤-galactosidase. These cells were then allowed to fuse with cells expressing the ⍀ fragment of
␤-galactosidase for 24 h. Fusion was stopped by lysing the cells, and ␤-galactosidase activity was
quantitated and normalized to HN expression. Every mutation in HN conferred increased fusion promotion relative to the clinical wild-type HN. Results depict means plus standard errors of the means (SEM)
(error bars) from three biological replicates consisting of three technical replicates each. Mutants were
compared with CI WT with one-way analysis of variance (ANOVA) following log transformation of data.
Values that are statistically signiﬁcantly different (P ⬍ 0.0001) from the value for the CI WT are indicated
by an asterisk.

examined several interacting properties of HN (see introduction) that are involved in
this process. We assessed the neuraminidase (receptor cleavage) activity and also
quantiﬁed the release of receptor-bearing erythrocytes (RBCs) from HN-expressing cells
as a measure of the balance between avidity and receptor-cleaving properties. Neuraminidase activity was measured through the cleavage of 2=-(4-methylumbelliferyl)-␣D-N-acetylneuraminic acid, sodium salt hydrate (4-MUNANA) by HN (Fig. 6A). As previously described, almost all the culture-adapted HN mutants displayed lower
neuraminidase activity than CI WT, ranging from roughly 10% (L555S) to 40% (R242K)
relative activity (4). The H552Q mutant had increased neuraminidase activity, with
roughly 260% activity relative to CI WT. We have previously shown that this mutation

A

B

FIG 6 Increase in fusion promotion by mutant HN correlates with a decrease in neuraminidase activity and a decrease in RBC release. (A) Neuraminidase activity
was quantiﬁed by measuring cleavage of 4-MUNANA. The observed values were normalized to expression of the HNs. Excluding H552Q (see Discussion),
neuraminidase activity is decreased in all the mutant HNs compared to the wild-type clinical isolate. Results depict means plus standard deviations from three
biological replicates consisting of three technical replicates each. Mutants were compared with CI wt with one-way ANOVA following log transformation of data.
*, P ⬍ 0.0001. (B) Release of sialic acid-bearing RBCs by HNs at pH 7.5 and 37°C. 293T cells transiently expressing HNs were allowed to bind RBCs at 4°C for
30 min, washed, and transferred to 37°C. The percentages of RBCs released at 15, 30, 60, and 120 min were determined (y axis). All the mutants have decreased
release of RBCs relative to the wild-type clinical isolate. Results depict means plus standard errors of the means (SEM) from three biological replicates consisting
of two technical replicates each.
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at H552 on HN confers both higher receptor avidity and intrinsically enhanced triggering of F and thereby augments fusogenicity, an effect that overrides the increase in
receptor cleavage (see the release assay below) (26).
Release of bound receptor-bearing RBCs by cell surface HNs reﬂects the balance of
neuraminidase activity, which would release the bonds tethering the cells, and avidity
of the HNs, which retain the bound cells (Fig. 6B). We quantiﬁed the amount of RBCs
released at several time points when incubated at pH 7.5 and 37°C. Differences
between the HNs was most readily observed at the earliest time point of 15 min, when
CI WT had the most release (~77%), whereas the mutant HNs all had less release,
reﬂecting either their higher receptor avidity, lower neuraminidase activity, or both. We
observed two separate groups of mutants in their capability to release RBCs. A more
rapidly releasing group—P241L, R242K, and S554N— had roughly 60% release at
15 min and complete release (~100%) after 120 min. In contrast, the more slowly
releasing group, consisting of H552Q, L555F, L555S, and N556D, had 5 to 15% release
at 15 min and 85 to 95% release after 120 min. As noted above, the higher receptor
avidity of HN can override the higher-than-WT neuraminidase activity.
Fitness of engineered recombinant HPIV-3 viruses is modulated by HN mutations. To assess the relevance of the HN adaptations in the context of authentic virus
and determine the ﬁtness of the culture-adapted viruses in immortalized cells and
human airway epithelium (HAE), we generated recombinant viruses bearing the HN
mutations of interest on the genetic background of our well-characterized HPIV-3
clinical virus CI-1 (4) and containing an enhanced green ﬂuorescent protein (EGFP)
cassette between the P and M genes (rHPIV3 CI-1–EGFP). Each engineered virus was
sequenced in full to conﬁrm the mutations of interest. These engineered viruses permit
us to evaluate the outcome of selection in terms of impact on ﬁtness. HAE cultures at
an air-liquid interface or CV-1 immortalized cell monolayer cultures were infected with
viruses bearing wild-type (wt) CI HN, CI HN P241L, CI HN R242K, CI HN H552Q, CI HN
S554N, and CI HN L555F and expressing EGFP. Compared to the wt CI, the viruses
bearing all the mutated HNs show more infected cells in the CV-1 cell monolayers after
3 days (Fig. 7A, arrows point to examples of individual infected cells); contrast wt CI-1
infection in the top photo to infection with viruses bearing individual HN mutations in
the subsequent photos, where these adaptations confer superior growth in cultured
cells as expected. The wt CI virus is handicapped in growth at day 1 compared to each
of the viruses bearing the individual mutations in HN (Fig. 7B, yellow squares), producing no detected progeny compared to a titer of 103 to 104 PFU/ml for each of the
viruses bearing a single adaptive HN mutation. The growth in CV-1 cells reveals that
while the clinical virus is severely handicapped in monolayer culture, the mutations that
emerged during the RhMK culture isolation process confer growth in these monolayer
cultures. While the wt CI shows negligible ﬁtness in monolayer culture compared to the
adapted viruses on day 1, by day 3 infectious virus is released into the supernatant ﬂuid
of the virus to cell culture. At day 7 however, adaptive mutations have appeared
(Table 1) and correlate with increased production of infectious particles (Fig. 7B, yellow
squares).
In HAE tissue, the wt CI-1 has a growth advantage over all the mutated viruses,
showing that the individual culture-adaptive HN mutations modestly impair infection of
HAE (Fig. 7B, orange circles). At day 7 after HAE infection, wt CI releases 1.8 ⫻ 105
infectious particles into the HAE apical surface, which is between 3 and 80 times more
particles than released by the mutant viruses. As expected based on our previous
studies (4), growth in HAE did not result in emergence of mutations (Table 1).
DISCUSSION
Mechanisms that affect respiratory virus-cell interplay in the context of humans are
ﬁnely tuned to the environment of the host (4, 5). To understand natural viral infection
and the features that govern infectivity and transmissibility in humans, we have
endeavored to analyze ﬁeld strains in airway tissues. We have shown for human
parainﬂuenza virus type 3 that conclusions drawn from laboratory strains can be
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FIG 7 Growth of recombinant HPIV-3 CI-1 EGFP and recombinant HPIV-3 CI-1 EGFP bearing mutated HNs
in CV-1 and HAE cells. (A) CV-1 cells were infected with 5,000 PFU of the different recombinant viruses
(wt CI HN or panel of mutants). Infected cells were observed using an epiﬂuorescence Nikon TS2R-FL
inverted microscope 3 days postinfection. (B) Titration of HPIV-3 CI-1 EGFP viruses (wt CI or HN mutants)
of either supernatant ﬂuid from CV-1 cells (squares) or virus collected from HAE cells (circles) 1, 3, and
7 days after infection (PFU/ml). The values represent titers performed in triplicate from a representative
experiment that has been repeated three times.

misleading with regard to the receptor interaction and viral fusion properties that
govern entry and ﬁtness in vivo (4, 5). Analysis of clinical strains suggests that the HN-F
fusion pairs of circulating HPIV-3 viruses maintain a balance of properties that result in
an inverse correlation between fusion in cultured cells and growth in vivo; the fusion
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TABLE 1 Allele frequency of CI-1 HN and mutant HPIV-3 strains
Allele frequency (%)a
Strain
CI-1

CI-1
CI-1
CI-1
CI-1
CI-1

HN
HN
HN
HN
HN

P241L
R242K
H552Q
S554N
L555F

HN residue
D216
E216
K553
E553
L555
F555

P0
97
3
100
0
100
0

CV1 7 days
90
10
95
5
88
12

HAE 7 days
100
0
99
0
100
0

L241
K242
Q552
N554
F555

99
100
100
99
99

99
99
99
99
100

100
99
100
99
100

aAllele

frequency at passage zero (P0) or after growth on CI-1 virus (CV1) for 7 days or on human airway
epithelium (HAE) for 7 days.

complex operates under speciﬁc constraints that govern viability in the different
environments of cell cultures and human beings.
We have previously used whole-genome sequencing of ﬁeld strains of HPIV-3
isolated from humans and grown only in airway cultures to analyze the diversity and
the commonalities of circulating strains of HPIV-3 (4). The sequences were used to
deﬁne functional and structural properties of proteins of circulating strains in order to
identify the genetic basis for properties that confer ﬁtness in the ﬁeld. While laboratoryadapted and CI airway-grown strains shared the basic properties of the HN-F fusion
complex—receptor binding, fusion triggering, receptor cleavage—the balance between these properties at each step is shared across all CIs we studied and different
from all laboratory strains. The CI fusion pairs all possessed lower fusogenicity and
decreased F activation compared to those of laboratory strains.
Here we carried out deep genomic screens of paired HPIV-3 clinical samples; one
portion of each sample was sequenced directly from the patient with no culture step,
while the other portion was exposed to brief culture for viral isolation in immortalized
rhesus monkey kidney (RhMK) cells, a standard cell line used in clinical laboratories for
virus identiﬁcation. We hypothesized that even during such brief periods of culture,
mutations arising in the HN-F fusion complex could be informative about features
essential for growth in humans that would be stringently selected against in culture.
HPIV-3 evolution upon exposure to culture was extraordinarily rapid and almost entirely
limited to the HN protein. Bioinformatic analyses of existing HN sequences revealed
that HN mutations that arose during brief exposure to culture are almost uniformly
found in consensus sequences from HPIV-3 that are either adapted to culture or
exposed to culture—and not found in HPIV-3 sequenced directly from clinical samples.
Deep sequencing of 118 newly derived HPIV-3 isolates and clinical samples revealed
that more than one-third of HPIV-3 isolates had subpopulations of HN dimer interface
variants that were not reﬂected in consensus sequences and were not present in HPIV-3
sequences obtained directly from clinical samples. The sequences were used to deﬁne
functional and structural properties that differ from laboratory-selected circulating
strains in order to identify the genetic basis for properties that may confer ﬁtness in the
ﬁeld.
The HN mutations that we identiﬁed in response to exposure to culture included
both novel and previously observed and characterized adaptations to immortalized
cells. Remarkably, all the mutations map to the dimer interface and receptor binding
site II of HN. These results point to the critical role of this region in the HPIV-3 entry
mechanism and for ﬁtness in vivo, as we have deduced from smaller-scale and mechanistic studies (4–7, 10). The H552 residue at receptor binding site II at the dimer
interface of HPIV-3 HN inﬂuences HN’s dimerization and its activation of F (6, 7). We
have shown that the presence of the glutamine at position 552 at the dimer interface
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of the HPIV-3 HN increases HN oligomerization and thereby modulates F triggering,
with this HN more actively triggering F (6, 10). When the virus bearing this mutated HN
was subjected to growth in human airway, it rapidly acquired a compensatory mutation, Q559R, which reduced fusion triggering and reduced HN dimerization. Structural
analysis of footprints of the dimer interfaces showed that when HN H552Q is present
in receptor binding site II, more of the interface residues are in contact with the
opposing monomer face. However, in the HN with the Q559R compensatory mutation
that permits growth in the airway, the dimer interface footprint shows decreased points
of contact. The dimer interface footprint pointed to several residues and domains
whose contact with the opposing monomer may be critical for the key functions
governed by HN’s receptor binding site II. The emergence of the H552Q mutation after
brief culture highlights both the ﬂexibility of HN’s site II to adapt to new conditions and
also the exquisite constraint of the virus’s fusion complex with respect to alterations in
the environment.
Adjacent to the H552 residue in the dimer interface, but not making contact in the
dimer interface footprint mentioned above, is N556, a residue we have previously
shown to be highly conserved in all clinical strains. This residue was previously found
to be an aspartic acid in laboratory-adapted strains, associated with a dramatic decrease in neuraminidase activity consistent with the overall high-receptor-contact/highfusion laboratory-adapted phenotype. In the present study, the N556D mutation
emerged during the very brief exposure to culture, highlighting the advantage of
lowering neuraminidase activity to reduce receptor cleavage for culture conditions
versus the importance of neuraminidase for human infection. Within the same cluster,
S554 was altered during culture adaptation; this is a residue that contacts the opposing
monomer in the dimer interface cluster (6, 39). The precise role of this residue in the
functions of the dimer region will be explored.
Strikingly, several mutations emerged in residues at the opposite side of the HN
dimer interface from the cluster at positions 552 to 556: residues 239, 241, and 242. The
points of contact of N240 and R242 with the opposing HN monomer in the dimer
interface footprint had been noted to correlate with fusion promotion and airway
adaptation; however, the function of these residues had been unexplored (6). The
selection for L239F, P241L, and R242K in the absence of mutations in the domain from
positions 552 to 556 suggests that the newly identiﬁed important region in the HN
dimer interface may act independently of receptor binding site II, and the functional
relationships between these two sites will be explored in future studies. Numerous
deep sequenced viral isolates also demonstrated P241L and R242K HN variants in the
absence of mutations in the domain from positions 552 to 556. The ﬁnding that this
second dimer interface domain undergoes rapid selection in the background of authentic clinical strains suggests that it may be relevant to ﬁtness in the airway.
To investigate the biological signiﬁcance of these adaptations, we generated singly
mutated HN molecules in the background of our well-characterized HPIV-3 clinical virus
HN, CI-1 (5), and generated recombinant viruses bearing the HN mutations on the
genetic background of CI-1. Brief exposure to culture, through this diversity of strategies, resulted in increased fusion promotion for all the HN variants tested: H552Q,
S554N, L555F, L555S, N556D, P241L, and R242K. While perhaps not unexpected based
on our previous hypotheses, the absolute consistency of this ﬁnding—that through a
range of speciﬁc mutations and speciﬁc functional and structural differences, the virus
arrives at increased fusion—is remarkable. Each individual HN mutation conferred
ﬁtness for recombinant virus infection of immortalized monolayer culture cells and for
spread of virus through the culture, compared to the parent wt CI.
To explore the components of HN’s properties that contribute to the enhanced
fusion promotion and infection properties for all the emerging HN mutants, we
assessed neuraminidase activity and HN’s release of receptor-bearing target cells, a
measure of the balance between receptor avidity and cleavage (26). We have shown
that clinical viruses, compared to laboratory strains, have a combination of high
neuraminidase, low avidity, low F triggering, resulting in lower fusogenicity. The HN
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mutants that emerged here all except for HN H552Q had decreased neuraminidase
activity. It is of interest that mutations at site II affect neuraminidase enzymatic activity,
since this site is not known to possess enzymatic activity, which resides in the
bifunctional active site at T193/D216 (12, 40–42). One mechanistic conjecture that will
be explored is that alterations or interactions at one HPIV-3 HN site (site I or II) modulate
the function of the other site, as we have shown for another paramyxovirus, Newcastle
disease virus, where receptor interaction at HN site I leads to the activation of site II (43,
44). These data may suggest an unexplored cross talk between site I and site II that
could alter neuraminidase activity allosterically. All the mutants—including HN
H552Q—showed reduced release of RBCs compared to the clinical strain. The HN
H552Q mutant’s decreased release of RBCs in the face of increased neuraminidase
activity relative to the CI WT is in agreement with our previous ﬁnding that this
mutation confers increased receptor avidity (26) that balances the receptor-cleaving
activity for an overall retention of contact. Interestingly, the H552Q mutation in the
lab-adapted HN background does not have higher neuraminidase activity (7), supporting the notion that the phenotype conferred by these sites may be modiﬁed in the
context of the genetic background. Collectively, the pattern is of enhanced receptor
engagement and an increase in fusogenicity that confers ﬁtness in vitro. The genetically
engineered viruses bearing the individual alterations in HN show that each is ﬁt for
growth in monolayer culture compared to the wt parent and less ﬁt for growth in HAE.
The mutations emerging during the brief viral isolation process thus led directly to
ﬁtness for growth in monolayer culture.
Interestingly, there is no single mutation or minor allele required for successful
growth in culture, although all samples in this study did produce at least one nonsynonymous minor allele on either the F or HN proteins. The minor alleles were extremely
biased toward mutations in the HN or F protein, with eight of ten cultures presenting
minor alleles on the HN protein and four presenting a minor allele on the F protein,
supporting the critical nature of the HN-F fusion complex for host adaptation (4).
Intriguingly, single mutations in HN did not confer fatal growth disadvantage in the
airway model, despite conferring ﬁtness in monolayer culture. It will be of interest to
determine whether an accumulation of several fusion-skewing mutations is necessary
for an absolute inability to grow in airway and whether a more sensitive experimental
system (i.e., infection in vivo) would be responsive to single alterations or only to a
greater dimer interface disturbance.
The genome sequences presented here provide a signiﬁcant resource for future
HPIV-3 genomic epidemiology and biochemical characterization, increasing the number of publicly available genomes by more than 40% (45, 46). We obtained full genome
sequence coverage from as few as an estimated 20,000 starting copies (4) and found
that relatively uniform whole viral genome coverage can be achieved with 100,000
paired-end reads, suggesting that many samples could be sequenced in a single MiSeq
run. Whole-genome viral sequencing from clinical samples should be both technically
and economically feasible, permitting investigators to avoid the use of laboratoryadapted strains of virus in immortalized cultured cell lines. The deep genome-wide
screens of paired clinical samples and viral isolates allow for simple, rapid interrogation
of viral evolution in the context of multiple clinical strain backgrounds. The methods
pursued here allowed for discovery of novel HN residues of interest that heretofore had
not been identiﬁed based on consensus sequence. Deep sequencing after rapid
selection pressure may allow for discovery of a greater number of novel mutations that
may be removed from the population by drift or competition with other variant
subpopulations after longer selection periods yet provide clues to function. Other
techniques that can more comprehensively proﬁle single mutations, such as deep
mutational scanning, are often limited by their use of singular backgrounds, often in
the context of culture-adapted strains, and focus on singular proteins.
Our results are consistent with an “uncertainty principle” for virology: the act of
attempting to study a clinical viral sample through commonly performed laboratory
procedures, such as viral culture in cell lines, affects the authenticity of the viral biology
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even before the ﬁrst passage. That viruses evolve uniquely in culture has been shown
for HPIV-3 (27); however, the extraordinarily rapid nature of evolution in culture, even
without passage, is notable. Most of the adaptive genotypes could be found as minor
alleles only by deep sequencing of clinical samples and viral isolates. With the increased
provision of deep coverage viral genomes obtained directly from clinical samples
due to diagnostic mNGS, experiments similar to the one outlined here will be
critical for potentially pathogenic viruses in order to assess whether previous viral
characterization studies apply to newly sequenced clinical samples (47, 48). For
HPIV-3, our results are consistent with the notion that use of authentic culture
models that better reﬂect HPIV-3 growth in vivo is critical if we are to understand
and characterize pathogenesis (4).
The speciﬁc mutations that emerged in the cultured samples, while disturbing from
the perspective of the “uncertainty” described above, provide a wealth of information
about HN domains that may be critical for ﬁtness in humans. In our focus on the
correlation of emerging HN mutations to function, we did not characterize all combinations of HN mutations, and for functional studies, we paired HNs with a lab-adapted
more fusogenic F protein in order to readily discern differences in HN properties;
ongoing studies will explore the potential for epistatic interactions in HPIV-3 evolution.
Of particular interest is the cluster of residues around P241 and R242 that were
uncovered as critical in this study. The interactions of these residues with the opposing
monomer, and these points of contact of this domain within the interface, were
suggested based on structural data to be relevant for fusion promotion (6). Future
studies will address the function of this HN dimer interface domain in HPIV-3 fusion and
cell entry.
MATERIALS AND METHODS
Sample description. The term “clinical sample” is used to describe primary nasal swabs in viral
transport media, while “viral isolate” or “culture isolate” is used to describe culture harvest from zero
passage virus (i.e., brief exposure to culture only during viral isolation). For paired clinical sample/culture
isolate sequencing, 200 l of nasal swab viral transport medium from nine patients from 2015 to 2016
with an HPIV-3 cycle threshold (CT) of ⬍25 was inoculated onto primary rhesus monkey kidney (RhMK)
cells (Quidel Diagnostics) and incubated on a roller drum at 37°C. The tubes were assessed for cytopathic
effect daily and conﬁrmed via hemadsorption with 1% guinea pig red blood cells (RBCs). Positive cultures
were harvested and stored at ⫺80°C.
Deidentiﬁed bronchial alveolar lavage (BAL) ﬂuid and nasal swab samples from 23 patients from 2016
used for prior clinical testing were stored at ⫺80°C and subjected to mNGS. In addition, 95 culture
harvests for which viral isolation was performed for prior clinical testing of BAL ﬂuid samples, nasal
swabs, and sputum samples from 2009 to 2016 at the University of Washington Virology Laboratory were
also stored at ⫺80°C and subjected to mNGS. Culture harvests from 2009 to 2016 were performed using
the same protocol detailed above for the 2016 paired sequencing experiment. Use of excess deidentiﬁed
clinical specimens was approved by the local University of Washington institutional review board (IRB)
(Protocol STUDY00000408). Sample metadata, including GenBank accession numbers for consensus
HPIV-3 genomes, are available in Table S1 in the supplemental material and associated with NCBI
BioProject 338014.
mNGS and amplicon sequencing. mNGS was performed as previously described (49). RNA was
extracted from 100 l of thawed culture harvests and clinical samples using the Zymo Viral RNA kit
(Zymo Research) and treated with Turbo DNase I (Thermo Fisher) for 30 min at 37°C (50). Doublestranded cDNA was made using random hexamers, SuperScript III reverse transcriptase (Thermo Fisher),
and Sequenase v2.0 (Thermo Fisher) and cleaned using Zymo-5 DNA Clean and Concentrator (Zymo
Research). mNGS libraries were produced by adding one-third volume of NexteraXT (Illumina) and
ﬁnished with 19 cycles of dual-indexed PCR ampliﬁcation and cleaned using 0.8⫻ Ampure beads
(Beckman Coulter) (51). Libraries were sequenced using one 192-bp and two 300-bp runs on an Illumina
MiSeq system. Libraries from the matched viral isolates were prepared twice in independent library
preparations and sequencing runs to control for artifacts of library preparation.
Amplicon sequencing was performed to investigate linkage between mutations recovered during
mNGS. Reverse transcription-PCR (RT-PCR) was performed using 35 cycles of the default parameters
(melting temperature [Tm], 55°C) in the One-Step RT-PCR kit (Qiagen) with PCR primers HPIV3-7477F (F
stands for forward) (5=-TACAGATAGGGATAATAACTGTAAA-3=) and HPIV3-8635R (R stands for reverse)
(5=-GCTTTGCTCCTAAGTTTTTTATATT-3=). Amplicons were puriﬁed using 1.0⫻ Ampure beads, and dualindexed TruSeq libraries were prepared using the Kapa HyperPrep kit with eight cycles of PCR ampliﬁcation (52).
Sequence data alignment and analysis. Sequencing reads were adapter and quality trimmed using
cutadapt and then aligned to the HPIV-3 reference sequence (NC_001796) with Geneious v9.1.7.
Consensus genomes were extracted for original patient samples, and culture sample sequencing reads
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were aligned to the sample consensus. Consensus genomes were visualized and mutations and minor
alleles with coverage of ⬎50⫻ and minor allele frequency (MAF) of ⬎5% were called using Geneious
9.1.7. The known locus of RNA editing in the phosphoprotein gene was not included among the variant
nonsynonymous alleles, nor were adenosine deaminase-like changes present on the same strand in P0
virus (affecting minor variants at R192G and I210V in CI-1 in Table 1).
Phylodynamic analysis. For phylodynamic analysis, coding nucleotide sequences from the 118
newly generated HPIV-3 genomes sequenced were extracted, concatenated, and aligned using Genious
v9.1.7 and MAFFT (53). The resulting alignment was used to generate a Bayesian Skyline tree with an
uncorrelated relaxed clock and Hasegawa, Kishino, and Yano (HKY) substitution model with gamma plus
invariant site heterogeneity model (four gamma categories) and three codon partitioning in BEAST v1.8.4
with a Markov chain Monte Carlo (MCMC) length of 10,000,000 iterations (54). Tree generation trace
information and evolutionary clock rates were gathered and analyzed using Tracer v1.6.0 (55). The
resulting trees were annotated and compiled using TreeAnnotator v1.8.4 and then annotated and scaled
in FigTree v1.4.2. The same phylodynamic protocol was also performed on all complete HPIV-3 genomes
present in NCBI NT as of 17 August 2017. Recombination detection was performed using RDP4’s RDP,
Chimaera, MaxChi, GENECOV, SiScan, and 3Seq algorithms with default settings (29).
To determine whether culture-associated HN amino acid changes were present in our paired sample
sequencing, we downloaded all partial and complete HPIV-3 HN sequences from NCBI NT as of 17 August
2017. Metadata on whether speciﬁc sequences originated from clinical sample or culture material were
gathered from the NCBI GenBank sequence record and associated manuscripts in PubMed. However, it
is not always possible to determine whether there was brief exposure to culture conditions prior to
sequencing. To show how the background of HN protein sequence could inﬂuence the amino acid
mutations selected during culture, a majority consensus amino acid sequence of HN protein from each
putative clinical sample was extracted and aligned using MAFFT. A neighbor-joining tree was created
using the Genious tree building algorithm, Jukes-Cantor distance method, and 100,000 replicates.
Functional characterization of HPIV-3 HN. The HN mutants examined in this study were generated
through site-directed mutagenesis of the previously constructed pCAGGS mammalian expression vector
with the CI-1 HN gene (4). Plasmids were Sanger sequence conﬁrmed prior to usage. Transfections with
plasmids were performed in HEK 293T cells using Lipofectamine 2000 in accordance with the manufacturer’s instructions. Cell surface expression of each HN was measured through standard immunoﬂuorescence assay procedures using monoclonal antibodies against HPIV-3 HN and used for normalization
as appropriate. Two monoclonal anti-HN antibodies used here (VT-3G9-B9 and VT-10F7-B11) were
custom-made by Aldevron using DNA immunization. Brieﬂy, a cDNA encoding HPIV-3 HN was cloned into
expression plasmids (pEGFP) (56). Groups of laboratory rats (Wistar) were immunized by intradermal
application of DNA-coated gold particles using a handheld device for particle bombardment (gene gun).
Serum samples were collected after a series of immunizations and tested in ﬂow cytometry on HEK cells
transiently transfected with the above expression plasmids. Antibody-producing cells were isolated and
fused with mouse myeloma cells (Ag8) according to standard procedures.
Measurement of fusion promotion. The ability of individual HNs to promote fusion was measured
through a ␤-galactosidase complementation assay as previously described (26, 40). HNs were paired with
the F protein from a lab-adapted strain (5), transiently transfected in HEK 293T cells, and then cell fusion
was quantiﬁed. Lab-adapted F partner molecules were used as previously described (4, 5), since fusion
is minimal when CI HN and F are expressed in pairs, and does not allow for quantitative comparisons.
Measurement of neuraminidase activity. Neuraminidase activity of HNs were measured as previously described (7, 41). HEK 293T cells were transiently transfected with individual HNs, collected through
detachment with 5 mM EDTA, washed with Dulbecco phosphate-buffered saline (DPBS) supplemented
with 1 g/liter D-glucose and 36 mg/liter sodium pyruvate (Gibco), then resuspended in CO2-independent
medium (pH 4.7) (Gibco). Cells were then added to 2=-(4-methylumbelliferyl)-␣-D-N-acetylneuraminic
acid, sodium salt hydrate (4-MUNANA) at a 1:1 ratio for a ﬁnal concentration of 10.2 mM. Fluorescence
was measured every 2 min for 1 h at 37°C with a microplate reader (Tecan).
Measurement of RBC release. The ability of HNs to release bound RBCs was measured as described
previously (9, 26). RBCs were bound to cells for 30 min at 4°C and washed to remove unbound RBCs.
CO2-independent medium (pH 7.5) was then added to the cells, and the cells were incubated at 37°C for
the appropriate times before being collected and replaced for the next time point. After 120 min, RBCs
that remained bound to the cells were lysed with ACK (ammonium-chloride-potassium) lysing buffer
(Gibco) and quantiﬁed by measurement of absorbance at 410 nm.
Immortalized cell culture. CV-1 (African green monkey kidney) and 293T (human kidney epithelial)
cells were grown in Dulbecco’s modiﬁed Eagle’s medium (DMEM) (Cellgro; Mediatech) supplemented
with 10% fetal bovine serum (FBS) and antibiotics at 37°C in 5% CO2.
Recombinant virus production and analysis. rHPIV3 clinical isolate 1 (CI-1)-EGFP is a recombinant
virus generated with a plasmid coding for the majority consensus sequence of HPIV-3 CI-1 (4, 5, 7)
obtained by deep sequencing and containing an enhanced green ﬂuorescent protein (EGFP) expression
cassette between P and M viral genes. All mutants were derived from this unique sequence. Recombinant viruses were generated by reverse genetics in the rHPIV3-CI-1-EGFP-F K108 background using a
modiﬁcation of methods previously described (57). Brieﬂy, 293T cells were seeded in six-well plates. The
following day, the cells were transfected using ProFection mammalian transfection system, calcium
phosphate kit (Promega) according to the manufacturer’s recommendations with 10 g of pFLC plasmid
encoding the full-length viral genome, 40 ng of pCAGGS-HPIV3 P, 40 ng of pCAGGS-HPIV3 L, 200 ng of
pCAGGS-HPIV3 N, 200 ng of pCAGGS-T7 polymerase, 100 ng of pCAGGS-HPIV3 lab-adapted HN, and
100 ng of pCAGGS-HPIV3 lab-adapted F (4). The following day, supernatant ﬂuids were replaced with
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DMEM supplemented with 10% FBS. Two days after transfection, the cells were mechanically detached
by pipetting up and down and overlaid onto CV-1 cells in a 10-cm culture dish. Cultured cells were
monitored by ﬂuorescence microscopy until 70% of the cells were infected. The medium was replaced
with DMEM without FBS, and cells were incubated for up to 2 days at 37°C in 5% CO2. Supernatant ﬂuid
was collected, centrifuged at 300 ⫻ g for 10 min at 4°C, aliquoted, and kept at ⫺80°C until use. All
recombinant viruses were sequenced at this stage using the same mNGS methods detailed above on
50 l of supernatant ﬂuid to conﬁrm the correct CI backbone and HN mutation sequences before use in
experiments.
Viral propagation in human airway epithelia. The HAE EpiAirway AIR-100 system (MatTek Corporation) consists of normal human-derived tracheo/bronchial epithelial cells that have been cultured to
form a pseudostratiﬁed, highly differentiated mucociliary epithelium closely resembling that of epithelial
tissue in vivo. Upon receipt from the manufacturer, human airway epithelium (HAE) cultures were
transferred to six-well plates (containing 1 ml medium per well) with the apical surface remaining
exposed to air and incubated at 37°C in 5% CO2. HAE cultures were infected with 5,000 PFU of
recombinant clinical isolate 1 EGFP (5) (referred to as CI-1-EGFP-F K108) at the apical surface for 90 min
at 37°C. The wild type (wt) CI-1-EGFP-F K108 or CI-1-EGFP-F K108 harboring single mutations in HN (i.e.,
P241L, R242K, H552Q, S554N, or L555F) was used. At 90 min, the medium containing the inoculum was
removed, and cultures were placed at 37°C and fed each day with 1 ml medium via the basolateral
surface. Viruses were harvested by adding 200 l of 1⫻ phosphate-buffered saline (PBS) with calcium
and magnesium chloride (MatTek Corporation) per well to the HAE cultures’ apical surface and equilibrating for 30 min at 37°C. The suspension was then collected, and viral titers were determined as
previously described (58). This viral collection was performed sequentially with the same wells of cells on
each indicated day postinfection.
Viral propagation in CV-1. CV-1 cultures were seeded in 24-well plates. Seventy percent conﬂuent
cells were infected with 5,000 PFU of recombinant CI-1-EGFP-F K108 (wt or harboring single mutations
in HN [i.e., P241L, R242K, H552Q, S554N, L555F]) at the apical surface for 90 min at 37°C. After 90 min,
the medium containing the inoculum was replaced with 1 ml of DMEM supplemented with 5% FBS. The
supernatant ﬂuid was then collected, aliquoted, and replaced with the same volume of DMEM supplemented with 5% FBS, and viral titers were determined as previously described (58). This viral collection
was performed sequentially with the same wells of cells on each indicated day postinfection.

SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/mBio
.00898-18.
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